Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue Ian Joseph Cohen Review Article 28 April 2017 Pages: 1057 - 1065
Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study Hang QuachDarrell WhiteMartin Gyger Original Article Open access 19 April 2017 Pages: 1067 - 1076
Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer Sotaro SadahiroT. SuzukiH. Nagase Original Article Open access 17 April 2017 Pages: 1077 - 1085
Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study Jianyuan ZhangShaojun ChenHongwei Jiang Original Article 20 April 2017 Pages: 1087 - 1097
A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer Feng SunRuizhe ZhaoShujie Xia Original Article 18 April 2017 Pages: 1099 - 1107
UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis Xuewei ChenLiping LiuJianxing He Original Article 13 May 2017 Pages: 1109 - 1117
Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer Yvonne Y. LauWen GuMichael Shi Original Article 19 April 2017 Pages: 1119 - 1128
CYT-Rx20 inhibits ovarian cancer cells in vitro and in vivo through oxidative stress-induced DNA damage and cell apoptosis Yen-Yun WangYuk-Kwan ChenShyng-Shiou F. Yuan Original Article 12 May 2017 Pages: 1129 - 1140
Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study Yun LengJian HouWenming Chen Original Article 12 May 2017 Pages: 1141 - 1149
Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy Christopher P. LeamonJoseph A. ReddyYu Wang Original Article 27 April 2017 Pages: 1151 - 1160
Adjuvant concurrent chemoradiotherapy with low-dose daily cisplatin for extrahepatic bile duct cancer Sang-Won KimO Kyu NohDukyong Yoon Original Article 26 April 2017 Pages: 1161 - 1167
Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer Masafumi IkedaHideaki TakahashiHideki Ueno Original Article 27 April 2017 Pages: 1169 - 1177
Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese Yuko TanabeChikako ShimizuYasuhiro Fujiwara Original Article 26 April 2017 Pages: 1179 - 1186
MITF suppression by CH5552074 inhibits cell growth in melanoma cells Satoshi AidaYukiko SonobeTakakazu Mizuno Original Article 26 April 2017 Pages: 1187 - 1193
In vitro and in vivo assessments of two novel hydrazide compounds against breast cancer as well as mammary tumor cells Elham MousaviShahrzad TavakolfarMona Salimi Original Article 27 April 2017 Pages: 1195 - 1203
FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer Y. L. XuR. YaoQ. Sun Original Article Open access 10 May 2017 Pages: 1205 - 1213
Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer Yu Nishijima-FutamiSeigo MinamiTakashi Kijima Original Article 28 April 2017 Pages: 1215 - 1220
A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors Tufia HaddadRui QinJulian Molina Original Article 05 May 2017 Pages: 1221 - 1227
The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum Takumi FujiwaraHirotsugu KenmotsuToshiaki Takahashi Original Article 28 April 2017 Pages: 1229 - 1237
Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab Georgina Meneses-LorenteChristine McIntyreMartin Weisser Original Article 11 May 2017 Pages: 1239 - 1247
Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme Anna M. Bielecka-WajdmanMarta LesiakEwa Obuchowicz Original Article 12 May 2017 Pages: 1249 - 1256
Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors Sandrine AspeslaghKunwar ShailubhaiJean-Charles Soria Clinical Trial Report 19 April 2017 Pages: 1257 - 1265
Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations Andrea BalleriniFederico MoroMassimo Zucchetti Short Communication 19 April 2017 Pages: 1267 - 1271
Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma Antoine Thiery-VuilleminEmeline OrillardBernard Royer Short Communication 27 April 2017 Pages: 1273 - 1276